Computational mass spectrometry for bacterial cell wall biology.

Mass spectrometry analytics for peptidoglycan structure determination, enhanced by machine learning — supporting antimicrobial resistance research and novel antibiotic discovery in collaboration with international research partners.

The same systematic, data-first analytical approach applies to other complex biological problems where the data exists but the answers don't.

PG Kern is the second of two ventures inside Verdares Kern, applying the same methodology to bacterial cell wall biology. Where Verdares AI is ready for commercial pilot deployment, PG Kern is at an earlier stage — actively producing scientifically promising results in collaboration with one of the world's leading peptidoglycan researchers.

Partner
University of Queensland
Domain
AMR · Bacterial cell wall
Method
Mass spec + ML
Stage
Validation stage
CSIRO
Data source
CSIRO
Domain
Regulated batch manufacturing · Yield
Method
Independent replication · CSIRO bioprocess data
Stage
In progress

One company. Two platforms.

Verdares AI is the commercial platform, for pharmaceutical batch manufacturing. PG Kern is the research platform, for bacterial cell wall biology. Both hold their analysis to the same standards.

  1. Evidence-graded

  2. Tested on unseen data

  3. Flags what the data can't support

  4. Same data, same answer

For research partners, academic collaborators, and patient investors.

If you are working in AMR, peptidoglycan biology, or antibiotic discovery — or if you back early-stage deep-tech with patience for proper validation — we are open to conversations.

Research enquirySee Verdares AI (Venture 01)